BTK and hematologic disorder: Ibrutinib (PCI-32765) is an orally available inhibitor of the BTK and has been approved for the treatment of several different types of hematological malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, or Waldenström’s macroglobulinemia34.